A Plethora of Treatment Options Brings Hope To Relapsed/Refractory Follicular Lymphoma Patients
source: pixabay.com

A Plethora of Treatment Options Brings Hope To Relapsed/Refractory Follicular Lymphoma Patients

Dr. Javier Munoz, the director of the Mayo Clinic's Lymphoma program in Phoenix, has recently conducted an interview with Kristie Kahl, the Vice President of content for the Cancer Network.…

Continue Reading A Plethora of Treatment Options Brings Hope To Relapsed/Refractory Follicular Lymphoma Patients
EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma

During the European Hematology Association (EHA)'s 26th Annual Meeting, taking place virtually, biopharmaceutical company Kite (part of Gilead) shared longer-term follow-up data on Yescarta (axicabtagene ciloleucel) for patients with relapsed…

Continue Reading EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma
Study: Treatment for Follicular Lymphoma Patients Must be Individualized
source: pixabay.com

Study: Treatment for Follicular Lymphoma Patients Must be Individualized

A recent study examined three different follicular lymphoma (FL) patients to try to better understand how the disease presents differently for different individuals. Ultimately, this study has reiterated the importance…

Continue Reading Study: Treatment for Follicular Lymphoma Patients Must be Individualized
AI Therapeutics’ LAM-002 Shows Positive Results in Treating Follicular Lymphoma and Hope for ALS
source: pixabay.com

AI Therapeutics’ LAM-002 Shows Positive Results in Treating Follicular Lymphoma and Hope for ALS

  AI Therapeutics is a biotechnology company that uses artificial intelligence to match drugs to indications. They do so through the use of their algorithm, Guardian Angel. This algorithm has…

Continue Reading AI Therapeutics’ LAM-002 Shows Positive Results in Treating Follicular Lymphoma and Hope for ALS
Bayer’s Aliqopa Receives Breakthrough Therapy Status for Marginal Zone Lymphoma
source: pixabay.com

Bayer’s Aliqopa Receives Breakthrough Therapy Status for Marginal Zone Lymphoma

According to a publication from Benzinga, the U.S. Food and Drug Administration has granted Breakthrough Therapy status to Bayer's relapsed follicular lymphoma drug Aliqopa (copanlisib) for the treatment of marginal…

Continue Reading Bayer’s Aliqopa Receives Breakthrough Therapy Status for Marginal Zone Lymphoma

Researchers Find the Future of Ofatumumab in Treating Follicular Lymphoma is Questionable

Ofatumumab as a Single Agent  Results of ofatumumab administered as a single agent with an extended induction (initial treatment) brought about a high response rate and it was well tolerated among follicular…

Continue Reading Researchers Find the Future of Ofatumumab in Treating Follicular Lymphoma is Questionable
The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)
qimono / Pixabay

The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)

The United States Food and Drug Administration has approved Copiktra™ (duvelisib). The drug is now approved as a treatment for adult patients diagnosed with refractory or relapsed chronic lymphocytic leukaemia…

Continue Reading The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)